Endotoxin Activity Assay-guided Polymyxin B Hemoperfusion: From Failed Trials to Biological Enrichment
Ricard Ferrer, Koki Namekawa, Shunichiro Urabe, Hiroshi Mukaida, Nao Umei, Toshiaki Iba · 2026
Read Endotoxin Activity Assay-guided Polymyxin B Hemoperfusion: From Failed Trials to Biological Enrichment by Ricard Ferrer, Koki Namekawa, Shunichiro Urabe, Hiroshi Mukaida, Nao Umei, Toshiaki Iba (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/openalex-w7166510838.txt.
Description
Ricard Ferrer, an intensive care specialist in Barcelona, led a 2026 review with Juntendo University co-authors on filtering endotoxin from the blood of patients in septic shock. The treatment, polymyxin B hemoperfusion, passes blood through a cartridge that adsorbs endotoxin, a bacterial toxin that drives organ failure. Early small trials encouraged use, but larger randomized trials without patient selection came back neutral.
A newer trial selected patients whose endotoxin activity assay fell in a defined mid-range and who had high organ dysfunction. In that group, treatment was linked to a high probability of reduced mortality, mainly at ninety days. The authors argue for this biologically enriched selection, while flagging doubts about the assay's results, feasibility, and reach.
Catalog record
| CREATOR | Ricard Ferrer, Koki Namekawa, Shunichiro Urabe, Hiroshi Mukaida, Nao Umei, Toshiaki Iba |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | OpenAlex / Juntendō Igaku/Juntendo igaku |